147 related articles for article (PubMed ID: 28157069)
21. Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli.
Spangler ML; Saxena S
Clin Ther; 2010 Jan; 32(1):53-6. PubMed ID: 20171411
[TBL] [Abstract][Full Text] [Related]
22. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
23. Of blood, bones, and broccoli: warfarin-vitamin K interactions.
Neafsey P
Home Healthc Nurse; 2004 Mar; 22(3):178-82; quiz 183-4. PubMed ID: 15017321
[No Abstract] [Full Text] [Related]
24. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
Siegmund HU; Burghaus R; Kubitza D; Coboeken K
Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
[TBL] [Abstract][Full Text] [Related]
25. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
26. Case report: dose adjustment of warfarin using genetic information and plasma concentration monitoring.
Aomori T; Fujita Y; Obayashi K; Sato H; Kiyotani K; Nakamura K; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2014 Jun; 39(3):319-21. PubMed ID: 24612117
[TBL] [Abstract][Full Text] [Related]
27. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
[TBL] [Abstract][Full Text] [Related]
28. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
[TBL] [Abstract][Full Text] [Related]
29. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
[TBL] [Abstract][Full Text] [Related]
30. Update on the interaction of rifampin and warfarin.
Kim KY; Epplen K; Foruhari F; Alexandropoulos H
Prog Cardiovasc Nurs; 2007; 22(2):97-100. PubMed ID: 17541320
[TBL] [Abstract][Full Text] [Related]
31. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Mrhar A; Breskvar K; Dolzan V
Pharmacogenomics J; 2005; 5(3):193-202. PubMed ID: 15824753
[TBL] [Abstract][Full Text] [Related]
32. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
33. Effects of cucurbitacin e, a tetracyclic triterpene compound from Cucurbitaceae, on the pharmacokinetics and pharmacodynamics of warfarin in rats.
Ding T; Zhang Y; Chen A; Tang Y; Liu M; Wang X
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):385-9. PubMed ID: 25250504
[TBL] [Abstract][Full Text] [Related]
34. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
35. Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects.
Moore KT; Byra W; Vaidyanathan S; Natarajan J; Ariyawansa J; Salih H; Turner KC
Br J Clin Pharmacol; 2015 Jun; 79(6):907-17. PubMed ID: 25475601
[TBL] [Abstract][Full Text] [Related]
36. Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
Rodrigues AD; Wood LS; Vourvahis M; Rowland A
Clin Pharmacol Ther; 2022 Feb; 111(2):425-434. PubMed ID: 34623637
[TBL] [Abstract][Full Text] [Related]
37. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.
Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
Clin Pharmacol Ther; 2018 Dec; 104(6):1182-1190. PubMed ID: 29569723
[TBL] [Abstract][Full Text] [Related]
39. Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method.
Inui N; Akamatsu T; Uchida S; Tanaka S; Namiki N; Karayama M; Chida K; Watanabe H
Clin Pharmacol Ther; 2013 Dec; 94(6):702-8. PubMed ID: 23974699
[TBL] [Abstract][Full Text] [Related]
40. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin.
Depré M; Van Hecken A; Oeyen M; De Lepeleire I; Laethem T; Rothenberg P; Petty KJ; Majumdar A; Crumley T; Panebianco D; Bergman A; de Hoon JN
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):341-6. PubMed ID: 15983826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
